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The effect of nut consumption on markers of inflammation and endothelial 
function: A systematic review and meta-analysis of randomised controlled trials 
Abstract 
Objectives To examine the effect of nut consumption on inflammatory biomarkers and endothelial 
function. Design A systematic review and meta-analysis. Data sources MEDLINE, PubMed, Cumulative 
Index to Nursing and Allied Health Literature and Cochrane Central Register of Controlled Trials (all years 
to 13 January 2017). Eligibility criteria Randomised controlled trials (with a duration of 3 weeks or more) 
or prospective cohort designs conducted in adults; studies assessing the effect of consumption of tree 
nuts or peanuts on C-reactive protein (CRP), adiponectin, tumour necrosis factor alpha, interleukin-6, 
intercellular adhesion molecule 1, vascular cell adhesion protein 1 and flow-mediated dilation (FMD). Data 
extraction and analysis Relevant data were extracted for summary tables and analyses by two 
independent researchers. Random effects meta-analyses were conducted to explore weighted mean 
differences (WMD) in change or final mean values for each outcome. results A total of 32 studies (all 
randomised controlled trials) were included in the review. The effect of nut consumption on FMD was 
explored in nine strata from eight studies (involving 652 participants), with consumption of nuts resulting 
in significant improvements in FMD (WMD: 0.79%(95% CI 0.35 to 1.23)). Nut consumption resulted in 
small, non-significant differences in CRP (WMD: −0.01 mg/L (95% CI −0.06 to 0.03)) (26 strata from 25 
studies), although sensitivity analyses suggest results for CRP May have been influenced by two 
individual studies. Small, non-significant differences were also found for other biomarkers of 
inflammation. conclusions This systematic review and meta-analysis of the effects of nut consumption 
on inflammation and endothelial function found evidence for favourable effects on FMD, a measure of 
endothelial function. Non-significant changes in other biomarkers indicate a lack of consistent evidence 
for effects of nut consumption on inflammation. The findings of this analysis suggest a need for more 
research in this area, with a particular focus on randomised controlled trials. 
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AbstrAct
Objectives To examine the effect of nut consumption on 
inflammatory biomarkers and endothelial function.
Design A systematic review and meta-analysis.
Data sources MEDLINE, PubMed, Cumulative Index to 
Nursing and Allied Health Literature and Cochrane Central 
Register of Controlled Trials (all years to 13 January 2017).
Eligibility criteria Randomised controlled trials (with 
a duration of 3 weeks or more) or prospective cohort 
designs conducted in adults; studies assessing the 
effect of consumption of tree nuts or peanuts on 
C-reactive protein (CRP), adiponectin, tumour necrosis 
factor alpha, interleukin-6, intercellular adhesion 
molecule 1, vascular cell adhesion protein 1 and  
flow-mediated dilation (FMD).
Data extraction and analysis Relevant data were 
extracted for summary tables and analyses by two 
independent researchers. Random effects  
meta-analyses were conducted to explore weighted 
mean differences (WMD) in change or final mean values 
for each outcome.
results A total of 32 studies (all randomised controlled 
trials) were included in the review. The effect of nut 
consumption on FMD was explored in nine strata 
from eight studies (involving 652 participants), 
with consumption of nuts resulting in significant 
improvements in FMD (WMD: 0.79%(95% CI 0.35 to 
1.23)). Nut consumption resulted in small,  
non-significant differences in CRP (WMD: −0.01 mg/L 
(95% CI −0.06 to 0.03)) (26 strata from 25 studies), 
although sensitivity analyses suggest results for CRP 
may have been influenced by two individual studies. 
Small, non-significant differences were also found for 
other biomarkers of inflammation.
conclusions This systematic review and meta-
analysis of the effects of nut consumption on 
inflammation and endothelial function found evidence 
for favourable effects on FMD, a measure of endothelial 
function.  
Non-significant changes in other biomarkers indicate 
a lack of consistent evidence for effects of nut 
consumption on inflammation. The findings of this 
analysis suggest a need for more research in this area, 
with a particular focus on randomised controlled trials.
PrOsPErO registration number CRD42016045424.
IntrODuctIOn
Chronic conditions such as type 2 diabetes and 
metabolic syndrome are known to be under-
pinned by a state of low-grade inflammation, 
which play a central role in disease progres-
sion and in the development of atheroscle-
rosis.1 2 Changes in this inflammatory state 
can be identified via biomarkers of inflam-
mation including C-reactive protein (CRP),3 
tumour necrosis factor-alpha (TNF-α),4 inter-
leukin-6 (IL-6)5 and the adhesion molecules 
intercellular adhesion molecule 1 (ICAM-1), 
vascular cell adhesion protein 1 (VCAM-1),6 
as well as anti-inflammatory biomarkers such 
as the adipocyte adiponectin.7 Endothelial 
dysfunction is a central component in the 
development and progression of atheroscle-
rosis, with brachial flow-mediated dilation 
(FMD), a non-invasive measure of endothelial 
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strengths and limitations of this study
 ► This is the first known systematic review and 
meta-analysis which examined the effect of nut 
consumption on inflammation and endothelial 
function, in studies which isolated the effect of nut 
consumption.
 ► The protocol for the review was preregistered, 
and the review followed the requirements of the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses statement.
 ► Risk of bias was assessed using the Cochrane 
Risk of Bias Tool, and the quality of the body of 
evidence was then determined using grading of 
recommendations assessment, development and 
evaluation (GRADE).
 ► The available evidence base for some of the 
biomarkers explored was small.
 ► There were variations in the included studies, such 
as participant health status, nut type and dose and 
study duration, although these factors were explored 
in subgroup analyses.
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function, found to be significantly associated with risk of 
cardiovascular events.8 
Given that markers of inflammation and endothelial 
function can indicate changes in disease development 
and progression, they can be used to explore the impact 
of consumption of specific foods on health. Nuts contain 
a wide range of nutrients and bioactive components 
which may moderate inflammation and the develop-
ment of endothelial dysfunction, such as alpha-linolenic 
acid, L-arginine, fibre and polyphenols.9 Habitual nut 
intake has been associated with reduced risk of cardio-
vascular disease,10 decreased incidence of the metabolic 
syndrome11 and decreased risk of diabetes.12 Clinical trials 
have previously explored the effects of nut consumption 
on markers of inflammation and endothelial function, 
with a range of effects observed.13–22 A systematic review 
and meta-analysis would consolidate and appraise the 
quality of this body of evidence, providing greater clarity 
where inconsistencies are observed. Even so, the effort is 
ongoing. For example, a recently published systematic 
review did not report significant effects of nut consump-
tion on CRP23 but did not include results of the large 
PREvención con DIeta MEDiterránea (PREDIMED) 
study.24 It is also possible to consider FMD as an outcome 
which this previous review did not consider. The aim of 
the review reported here was to examine the effect of nut 
consumption on markers of inflammation and endothe-
lial function (CRP, adiponectin, TNF-α, IL-6, ICAM-1, 
VCAM-1, FMD) in adults. It was hypothesised that the 
regular inclusion of nuts in a diet would improve markers 
of inflammation and endothelial function.
MEthODs
This systematic review and meta-analysis followed the 
requirements of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses statement25 
(see online supplementary material 1). The review was 
registered in International Prospective Register of System-
atic Reviews (PROSPERO) (http://www. crd. york. ac. uk/ 
PROSPERO; registration number: CRD42016045424).
study selection
A systematic search of the databases MEDLINE, PubMed, 
Cumulative Index to Nursing and Allied Health Litera-
ture and Cochrane Central Register of Controlled Trials 
was conducted (all years to 13 January 2017). In line 
with recommendations by Rosen and Suhami,26 both 
MEDLINE and PubMed were searched to ensure recent 
studies were detected. Furthermore, where possible, 
Medical Subject Heading terms as well as free-text search 
terms were used in the search.26 Reference lists of eligible 
articles and relevant reviews were also reviewed for poten-
tial studies. An example of the search strategy used is 
shown in online supplementary material 2. Articles were 
restricted to those published in English.
To be included in this review, studies were required 
to meet the following inclusion criteria: (1) randomised 
controlled trial (including both parallel and cross-
over designs) or prospective cohort design; (2) studies 
conducted in humans aged 18 years or older; (3) studies 
assessing the effect of consumption of tree nuts or peanuts 
on an outcome of interest (CRP, adiponectin, TNF-alpha, 
IL-6, ICAM-1 VCAM-1, FMD), where the effect of nut 
consumption could be isolated. The outcomes of interest 
were selected to cover a suite of biomarkers regularly 
used in the literature to indicate changes to inflamma-
tion and endothelial dysfunction, including in previous 
meta-analyses exploring the effects of foods and dietary 
patterns27 28; (4) studies with an intervention duration of 
3 weeks or more (in the case of randomised controlled 
trials). This minimum duration was selected to ensure 
included studies reflected sustained changes to inflam-
mation and endothelial function and to align with similar 
cut-offs used in other meta-analyses exploring the impact 
of dietary components on inflammation27 or the effect of 
nut consumption on other physiological measures.29 30 In 
addition, the following exclusion criteria were applied: (1) 
studies involving pregnant or breastfeeding women and 
(2) studies exploring the effects of nut oils or extracts.
Articles were screened based on title and abstract. Full 
texts were retrieved in the case that an abstract was not 
available or did not provide sufficient information to draw 
a conclusion regarding inclusion in the current review. 
In the case that results from one study were reported in 
multiple articles, all articles were checked to avoid dupli-
cation of study populations in the analysis or overlooking 
new information on outcomes. Where different informa-
tion on outcomes were reported across articles, all rele-
vant articles were included in line with the guidelines of 
the Cochrane Handbook.31 Where the same outcomes 
from a single study were reported across multiple arti-
cles, decisions relating to article inclusion were based first 
on the length of follow-up for the outcome and then by 
sample size.
Data extraction
The following data were extracted from each study: cita-
tion, country, sample size, participant age and body mass 
index, health status, study design, study duration, nut type, 
nut dose, details of control arm and background diet. 
Mean changes in relevant outcomes were extracted where 
possible, and in the case that these data were not avail-
able, mean final values were retrieved as recommended 
by the Cochrane Handbook for Systematic Reviews of 
Interventions.31 Study authors were contacted for addi-
tional details if the published article did not provide 
sufficient information. Where a study involved more than 
one intervention group meeting the inclusion criteria, 
data for the two intervention groups were combined as 
recommended by the Cochrane Handbook.31 In the case 
of the PREDIMED study,24 which included two interven-
tion arms featuring a Mediterranean diet supplemented 
with either nuts or olive oil and a low fat control arm, data 
from the arm receiving the Mediterranean diet with olive 
oil was treated as the comparator group. This decision was 
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made to ensure outcomes were not confounded by differ-
ences in the background diet of the two groups. Where 
studies reported median rather than mean, medians were 
used in the meta-analysis, and SD was imputed from IQR.
Abstract screening, study inclusion and exclusion 
and data extraction were conducted independently by 
two authors (EN and VG), and any disagreements were 
resolved via consensus.
statistical analyses
Review Manager (RevMan V.5.3 (Copenhagen: The 
Nordic Cochrane Centre, the Cochrane Collaboration, 
2014) was used to conduct random effects meta-analyses 
to determine the weighted mean differences (with 95% 
CIs) in change or final mean values for each outcome. 
In initial analyses, cross-over studies were treated in the 
same way as parallel studies by comparing measurements 
from the intervention periods with the control periods 
via a paired analysis, as the most conservative approach 
to managing cross-over studies.31 To explore whether this 
approach affected the final result by underweighting these 
studies, paired analyses of cross-over studies using correla-
tion coefficients of 0.25, 0.5 and 0.75 were conducted as 
sensitivity analyses.
The proportion of total variation attributable to 
between-study heterogeneity was estimated using the I2 
test statistic.32 An I2 value of 75% or greater was deemed to 
indicate a high level of inconsistency, based on the recom-
mendations by Higgins et al.32 I2 values were generated 
for each analysis, including subgroup analyses (outlined 
below). For outcomes with 10 or more strata, funnel 
plots were generated to explore small study effects, with 
Egger’s test used to determine the extent of funnel plot 
asymmetry.33 Where funnel plot asymmetry was detected, 
sensitivity analyses using the trim-and-fill method were 
conducted to explore potential publication bias.34 Egger’s 
test and the trim-and-fill method were conducted using 
Stata V.15 (StataCorp, 2017). In addition to the correla-
tion coefficient sensitivity analyses outlined previously, 
sensitivity analyses were also conducted to explore the 
effect of removing studies with imputed SD from analyses 
and of removing each individual study in meta-analyses 
(‘leave-one-out’ analysis). Prespecified subgroup analyses 
were also conducted, based on study duration (less than 
3 months vs more than 3 months), risk of bias and nut 
type. For the purpose of subgroup analyses, studies which 
compared the effects of two types of nuts to a control35 36 
were classified as ‘mixed nut studies’. Post hoc subgroup 
analyses were conducted based on health status of partic-
ipants, whether the energy value of nuts was substituted 
for other foods, study design (parallel vs cross-over) and 
nut dose (<50 g per day vs >50 g per day29).
Quality assessment
The Cochrane Collaboration Risk of Bias tool31 was used 
to determine the risk of bias in included studies. EN and 
VG separately appraised the risk of bias and disagreements 
were resolved by discussion until consensus was reached. 
The quality of the body of evidence was then determined 
using grading of recommendations assessment, develop-
ment and evaluation (GRADE),37 which considers study 
design, risk of bias, inconsistency, indirectness, impreci-
sion and other considerations such as publication bias. 
GRADEproGDT software V.2015 (GRADEpro (www. 
gradepro. org) McMaster University, 2014) was used to 
conduct the quality of evidence appraisal.
rEsults
characteristics of included studies
A total of 5200 articles were identified from the system-
atic search and review of relevant reference lists. After 
applying exclusion criteria, 36 articles describing 32 
studies (34 strata in pooled analyses) were included in the 
systematic review and meta-analysis. The process of study 
inclusion and exclusion is shown in figure 1. Data access 
is available on request.
Characteristics of included studies are shown in table 1. 
All included studies were randomised controlled trials. 
Although prospective cohort study designs were also 
considered, no cohort studies met the overall inclusion 
criteria for the review. The most common reason was that 
the cohort studies did not report on the association between 
nut consumption and an outcome of interest. Fourteen 
studies had a parallel design13 15 16 19 35 38–50 and 17 had a 
cross-over design.14 17 18 20–22 36 51–60 One study61 combined 
a parallel and cross-over design, where participants were 
initially randomised to one of two parallel groups (energy 
adjusted or ad libitum diet). In this study, each group then 
took part in the cross-over part of the study consisting of 
a walnut included period and a walnut excluded period. 
Among all studies, duration ranged from 4 weeks to 
5 years, although 2014 15 17 18 21 22 35 36 41 42 47 49 52–56 58–60 out 
of 32 studies (63%) had a duration of less than 3 months. 
Studies were conducted in Spain,16 18 20 36 38 43–47 53 the 
USA,14 17 22 39 41 48 50 52 54 55 58 59 61 Australia,49 51 India,19 40 
Canada,56 South Korea,15 China,21 Brazil,42 South Africa,35 
Iran,57 New Zealand13 and Germany.60 Studies included 
participants who were healthy,49 52 had risk factors for 
chronic disease such as overweight or obesity, dyslipidaemia, 
hypertension or prediabetes,13 17 18 20 36 40–42 47 50 51 53 55 56 58–60 
had type 2 diabetes mellitus,14 21 22 48 57 met the criteria for 
metabolic syndrome,15 16 19 35 38 had diagnosed coronary 
artery disease54 or included a mixture of the aforemen-
tioned conditions.39 43–46 61 Included studies examined the 
effects of consumption of a range of tree nuts including 
walnuts,17 18 22 39 50 52 53 55 60 61 almonds,21 41 48 54 56 58 pista-
chios,14 19 20 40 57 59 hazelnuts,13 47 mixed nuts15 16 38 43–46 and 
Brazil nuts,49 as well as peanuts.42 51 In addition, two studies 
included multiple intervention arms, featuring a different 
type of nut in each (walnuts and cashews,35 and walnuts 
and almonds36) compared with a control arm. Nuts were 
consumed in either prescribed doses, ranging from 
approximately 1849 to 85 g per day54 or were designed to 
provide a set proportion of dietary energy, so the amount 
would vary for individuals.14 18 19 21 35 50 58 59 Background 
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Figure 1 PRISMA25 flow diagram of study selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-
Analyses.
diets consisted of either participant’s habitual diet or a 
prescribed diet aligned with healthy lifestyles such as the 
National Cholesterol Education Program (NCEP) Step I 
or II diet, a Mediterranean-style diet, the Therapeutic Life-
style Changes diet or another prudent style diet in line with 
dietary guidelines. Six studies provided all or the majority 
of foods under controlled feeding conditions.14 21 35 55 58 59 
Twenty-two studies14 17–22 35 36 39 40 42–47 50 53–56 58–60 prescribed 
diets accounting for the energy value of the nuts, either 
quantitatively through dietary modelling (including the 
energy value of the nuts within the total energy value of 
the diet) or qualitatively by encouraging participants to 
substitute nuts for items with similar energy values. One 
study61 included an intervention group where partici-
pants were advised on food substitutions to account for 
the energy value of the provided nuts and another inter-
vention group where energy intake was not prescribed 
(ad libitum food consumption). During the control diets 
or periods, participants typically consumed a similar diet 
but without nuts, although some studies included control 
diets with a specific product substituted for the nuts, 
such as eggs,52 olive oil,36 43–46 muffins56 and chocolate,41 
among others. Only two studies42 50 stated they prescribed 
a set energy restriction for both intervention and control 
groups; all other studies used isocaloric diets for weight 
maintenance or ad libitum diets. No studies reported a 
significant difference in weight loss between the interven-
tion and control groups.
Effect of nut consumption on study outcomes
Flow-mediated dilation
A total of nine strata from eight studies14 17 18 22 40 54 59 61 
explored the effect of nut consumption on FMD. Of the 
nine strata, five explored the effect of walnut consump-
tion on FMD,17 18 22 61 and six had a duration of less than 
3 months.14 17 18 22 54 59 The meta-analysis showed that nut 
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Figure 2 Difference in FMD (%) between nut consumption and control (presented as subgroups based on mean final or 
change values for readability). Diamond indicates weighted mean difference with 95% CIs. FMD, flow-mediated dilation.
consumption was associated with a significant increase in 
FMD (figure 2 and table 2). Sensitivity analyses indicated 
that excluding any one study did not substantially alter 
the effect (data not shown). The effect estimate was also 
similar after using different correlation coefficients (CC: 
0.5; see online supplementary material 3; CC: 0.25 and 
0.75, data not shown). No significant differences were 
found for subgroup analyses (see online supplementary 
material 4) although it was noted that when subgroup 
comparisons were made according to nut type, only the 
walnut subgroup found significant improvements in 
FMD.
C-reactive protein
A total of 26 strata from 25 studies13–16 18 19 21 35 36 40–42 44 47–52 54–58 60 
explored the effect of nut consumption on CRP. Almonds 
were the most common nut type used in these analyses 
(seven strata21 41 48 54 56 58), followed by walnuts18 50 52 55 60 and 
mixtures of more than one nut type15 16 35 36 44 (each used in 
five strata). A total of 17 strata from 16 studies had a dura-
tion of less than 3 months.14 15 18 21 35 36 41 42 47 49 52 54–56 58 60 
When all studies were included in the meta-analysis, nut 
consumption resulted in non-significant differences in 
CRP (figure 3 and table 2). The overall effect was rela-
tively unchanged when studies with imputed SD were 
removed from the analysis (table 2). Sensitivity analyses 
identified two studies15 52 that contributed substantially 
to the pooled result, as when they were excluded from 
the meta-analysis, the reductions in CRP were significant 
(see online supplementary material 5). In addition, the 
use of different correlation coefficients did not change the 
overall effect found (CC: 0.5, see online supplementary 
material 3; CC: 0.25 and 0.75, data not shown). Subgroup 
analyses indicated that statistically significant differences 
were found between studies which included the energy 
value of nuts in the prescribed diet compared with those 
that did not (see online supplementary material 4). An 
effect estimate of −0.23 mg/L (−0.44 to –0.01) was found 
for studies in which diets incorporated the energy value 
of nuts, while an effect estimate of −0.00 mg/L (−0.06 to 
0.05)) was found for studies which did not incorporate the 
energy value of nuts (χ²=3.99, df=1 (P=0.05), I²=74.9%). 
When studies were grouped according to nut dose, an 
effect estimate of −0.00 mg/L (0.00 to 0.00) was found 
for studies which included less than 50 g of nuts/day, 
while an effect estimate of −0.34 mg/L (−0.63 to–0.06)) 
was found when 50 g or more were used (χ²=5.74, df=1 
(P=0.02), I²=82.6%). Borderline significant differences 
(P=0.05) were found when studies with a parallel design 
were compared with cross-over studies. However, when 
either of the studies identified in the sensitivity anal-
ysis15 52 were excluded, these subgroup analyses no longer 
produced significant results (data not shown).
Adiponectin, TNF-α, IL-6, ICAM-1, VCAM-1
The meta-analysis showed that consumption of nuts did 
not result in significant differences in adiponectin, TNF-α, 
IL-6, ICAM-1 or VCAM-1 (table 2 and online supplemen-
tary material 6). In the case that pooled analyses featured 
studies with imputed SDs (IL-6, ICAM-1, VCAM-1), 
excluding these studies did not substantially change the 
effect estimates (table 2). Sensitivity analyses indicated 
that excluding any one study did not substantially alter 
the effect (data not shown). Overall effects also did not 
change when different correlation coefficients were used 
for cross-over studies (CC: 0.5, see online supplemen-
tary material 3; CC: 0.25 and 0.75, data not shown). No 
significant differences between subgroups were observed 
(see online supplementary material 4).
small study effects
Funnel plots were generated for outcomes with 10 or 
more strata (CRP, IL-6, ICAM-1 and VCAM-1) (see online 
supplementary material 7). Egger’s test indicated 
asymmetry in funnel plots for CRP (bias=−0.68 (95% 
CI=−1.06 to -0.31), P=0.001) and IL-6 (bias=−0.81 (95% 
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Figure 3 Difference in C-reactive protein (mg/L) between nut consumption and control (presented as subgroups based on 
mean final or change values for readability). Diamond indicates weighted mean difference with 95% CIs.
Figure 4 Risk of bias assessment as proportion of total strata.
CI=−1.45 to −0.16), P=0.02), suggesting the presence of 
small study effects which may have been attributable to 
publication bias. Use of the trim-and-fill method did not 
change these results (data not shown). Funnel plot asym-
metry was not detected for ICAM-1 or VCAM-1 (data not 
shown).
risk of bias and quality of the body of evidence
The risk of bias was determined for each strata using the 
Cochrane Risk of Bias Tool, and the results of the assess-
ment are shown in figure 4 and online supplementary 
materials 8 and 9. The quality of the evidence was ‘high’ 
for FMD, ICAM-1 and VCAM-1. The quality was down-
graded to ‘moderate’ for TNF-α due to risk of bias and 
to ‘low’ for CRP and IL-6 due to both risk of bias and the 
possibility of publication bias. The quality of the evidence 
for adiponectin was downgraded to ‘very low’ due to risk 
of bias, inconsistency and imprecision (see online supple-
mentary material 10).
DIscussIOn
The results of this systematic review and meta-analysis 
suggested favourable effects of nut consumption on 
FMD, a measure of endothelial function. These findings 
align with a review conducted in 2011 by the European 
Food Safety Authority (EFSA), which explored the effects 
of walnut consumption on endothelium-dependent 
vasodilation.62 A meta-analysis was not part of the EFSA 
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report,62 but the present study provides a meta-analysis 
that includes more recently published research.17 61 It also 
includes studies investigating other types of nuts.14 40 54 59 
Subgroup analyses found significant improvements in 
FMD only in those studies using walnuts, consistent with 
the EFSA report which only examined walnut consump-
tion, although the test for subgroup differences in the 
present study did not reach statistical significance. This 
may have resulted from the small number of studies avail-
able for assessing FMD. Having few studies may have also 
played a role in the lack of significant effects observed in 
other FMD subgroup analyses. These include studies in 
participants with type 2 diabetes or studies lasting longer 
than 3 months. Further research is therefore required in 
this area.
Despite the small sample size, the findings of this review 
relating to FMD are of value due to the known associa-
tions between FMD and future cardiovascular events. A 
meta-analysis of cohort studies found a significant reduc-
tion in risk of cardiovascular events per 1% increase in 
FMD (relative risk: 0.872 (95% CI 0.832 to 0.914)).8 In 
comparison, the present study found an effect estimate 
of 0.79% for nut consumption compared with controls, 
suggesting these results are likely to be of clinical rele-
vance to future cardiovascular risk. There are a number 
of mechanisms by which nuts, and walnuts in particular, 
could improve FMD. FMD is a measure of endothelial 
dysfunction,63 a condition characterised by reduced 
availability of the vasodilator nitric oxide (NO).64 Nuts 
contain high levels of L-arginine,65 an amino acid which 
acts as a precursor to NO.66 Walnuts in particular are rich 
in alpha-linolenic acid, a polyunsaturated fatty acid that 
has been suggested to increase membrane fluidity, thus 
also increasing nitric oxide synthesis and release.67 The 
antioxidant content of nuts may also play a role in the 
improvements in endothelial function observed.9
Our finding of no significant effects on inflammatory 
biomarkers CRP, TNF-α, IL-6, ICAM-1, VCAM-1 or the 
anti-inflammatory biomarker adiponectin reflects the 
body of evidence available at this time. There may be 
effects with CRP but characteristics of the study sample 
or design of the dietary intervention may influence the 
ability to detect these effects. Sensitivity analyses indi-
cated that results may have been disproportionally 
influenced by a small number of studies. Exclusion of 
either one of two studies15 52 resulted in the meta-anal-
ysis yielding significant reductions in CRP following nut 
intake, suggesting these two studies were responsible for 
the results found. This appears to be the result of low 
reported CRP values and correspondingly small standard 
errors, resulting in these studies receiving substantially 
higher weighting than other studies in the pooled anal-
ysis. The study sample may in part explain these findings, 
as the study by Burns-Whitmore et al52 was conducted in 
healthy lacto-ovo vegetarians. Consumption of a plant-
based diet has been associated with decreased inflamma-
tion.68 In contrast, Lee et al15 explored the effect of nut 
consumption in individuals with metabolic syndrome, 
which is typically associated with elevated CRP levels.69 
Reported units were confirmed with study authors.
The findings of this review may also have been influ-
enced by the design of the dietary interventions included. 
Subgroup analyses found significant reductions in CRP 
when studies incorporated 50 g or more of nuts per day. 
This finding aligns with previous research suggesting a 
dose–response effect of nut intake on other outcomes 
such as cholesterol.70 However, these findings should be 
interpreted with caution, as several studies14 18 19 21 35 50 58 59 
incorporated nuts as a proportion of total energy, resulting 
in substantial variation between individuals in the dose 
consumed. Furthermore, whether the energy value of 
nuts was adjusted for in the total diet may have influenced 
results. Subgroup analyses suggested significant effects on 
CRP were only found when the energy provided by nuts 
was accounted for either by dietary modelling or advice to 
substitute other foods for nuts. This aligns with a previous 
review by our group which highlighted the importance 
of considering total energy intake in trials examining the 
effect of vegetable intake on weight loss.71 There is also 
evidence to suggest markers of inflammation such as CRP 
may be reduced following periods of energy restriction,72 
highlighting the importance of considering total energy 
intake when exploring the effects of individual foods. 
The design of the control arm may have also impacted on 
results, as several studies36 43–46 compared intake of nuts 
with a control intervention which also had the potential 
to influence inflammation and endothelial function, 
for example olive oil.27 The potential impact of control 
groups on underestimating intervention effects has previ-
ously been highlighted in the weight loss literature.73 
Trials aiming to explore the influence of specific foods on 
health outcomes must carefully consider the design of the 
dietary intervention and control arms and avoid increases 
in total energy intake which could skew results.
The heterogeneity in study design elements, partic-
ularly related to dietary intervention, may explain why 
reviews exploring the effects of nut consumption on 
inflammation have found varying results. Although 
including fewer studies than in our review, a recently 
published review by Mazidi et al23 also found non-sig-
nificant differences in inflammatory biomarkers (CRP, 
IL-6, adiponectin, ICAM-1 and VCAM-1), although in 
contrast to our review, they observed a small increase 
in CRP levels. The review by Mazidi et al23 appeared to 
have broader eligibility criteria which also included post-
prandial studies and those exploring the effects of soy 
consumption. In another review, Barbour et al74 reported 
significant reductions in CRP following nut consumption. 
It should be noted however, that Barbour et al74 included 
studies where nut consumption was encouraged as part 
of a suite of favourable dietary changes not matched in 
control groups, which means that the effect of the nuts 
themselves could not be isolated. In these circumstances, 
it may not be possible to show whether effects observed 
were the result of increases in nut intake or the wider 
dietary changes occurring. We avoided this problem by 
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excluding studies with a portfolio of dietary changes not 
matched in the control group or by treating a comparable 
intervention group as the ‘control’ (or comparator), as 
in the case of the PREDIMED study.24 Nevertheless, nuts 
appear in healthy dietary patterns, and we have previously 
shown that consumption of a healthy dietary pattern 
(many of which include habitual nut intake) results in 
significant reductions in CRP.75
It should be noted that while the current analysis found 
favourable effects of nut consumption on a marker of 
endothelial dysfunction, the lack of evidence for effects 
on cell adhesion molecules VCAM-1 and ICAM-1 suggests 
changes in endothelial cell activation may not have 
occurred. Given that the inflammatory cytokines which 
characteristically induce endothelial cell activation (for 
example TNF-α and IL-6)64 also appeared unchanged, 
the lack of difference found for ICAM-1 and VCAM-1 is 
perhaps not surprising. More research on this cluster of 
molecules will be informative.
This review had a number of strengths. It used a 
systematic methodology following current guidelines 
for systematic reviews, including prospective registration 
and used the Cochrane Risk of Bias tool and GRADE 
method to evaluate the quality of evidence. We consid-
ered a range of biomarkers associated with inflammation 
and endothelial function, including the anti-inflam-
matory adipocyte adiponectin. These biomarkers were 
selected to reflect changes in disease progression and 
amelioration to explore mechanisms responsible for the 
favourable effects of nut consumption on cardiovascular 
disease10 and other chronic conditions.11 12 However, 
we fully acknowledge that the measures explored here 
are not interchangeable with disease endpoints such as 
mortality and morbidity. The size of the evidence base, 
including the small number of participants available for 
analyses of individual biomarkers, is a limitation, partic-
ularly with respect to generalisability and strength of 
the evidence. Furthermore, although we were unable to 
explore the distribution of the published data included 
in this meta-analysis, the fact that several studies reported 
median values rather than means suggests some of the 
data may have been skewed, which may have impacted on 
our analyses.
The heterogeneity of the evidence base included can 
be also considered a limitation of this review. Variation 
existed as a result of participant health status, nut type 
and dose and study duration, although these factors 
were explored in subgroup analyses. Statistically signif-
icant subgroup differences were found only for CRP 
when studies were grouped according to whether they 
incorporated the energy value of nuts into the diet and 
based on nut dose (<50 g/day vs >50 g/day). However, 
due to the small number of studies, it is possible that 
other subgroup differences may have been found if the 
sample size was larger. For example, borderline signifi-
cant differences (P=0.05) were found between the study 
designs, with larger reductions in CRP found for cross-
over design studies. As the nature of cross-over studies 
eliminates between-subject variation,76 they may provide 
superior insights when exploring the impact of dietary 
interventions on biomarkers such as CRP; however, 
their results may also be impacted by carry-over effects.31 
Given the short or absent wash-out periods of some of 
the included studies,18 36 51 55 58 the potential impact of 
carry-over effects cannot be ruled out. Background diets 
also varied between studies, with some studies prescribing 
diets based on dietary guidelines, whereas others allowed 
participants to follow their habitual diet, which may 
have varied substantially between individuals. Analysis of 
funnel plots suggested the results for CRP and IL-6 may 
have been influenced by small study effects (which could 
indicate publication bias), which resulted in downgrading 
the quality of the evidence for these outcomes. Funnel 
plot asymmetry remained after sensitivity analyses were 
conducted. These findings suggest the need for more 
research in this area, with a particular focus on the regis-
tration of study protocols with detailed information on 
primary and secondary outcomes, to reduce the potential 
for publication bias.
This systematic review and meta-analysis of the effects 
of nut consumption on inflammation and endothelial 
function found evidence for favourable effects on FMD, 
a measure of endothelial function. Non-significant differ-
ences in CRP, adiponectin, TNF-α, IL-6, ICAM-1 and 
VCAM-1 suggest a lack of consistent available evidence for 
effects of nut consumption on inflammation, although 
the results for CRP should be interpreted with caution 
due to the large influence of single studies on the pooled 
results. The findings of this review provide further insight 
into the mechanisms by which nut consumption may 
exert favourable effects on the risk of chronic conditions 
such as cardiovascular disease. The findings also build 
on previous research such as the 2011 EFSA report62 on 
walnut consumption and endothelial-dependent vasodi-
lation and reinforce the value of including nuts within a 
healthy dietary pattern. However, the small evidence base 
for FMD and the observed lack of consistency in findings 
relating to inflammation suggest a need for more research 
in this area, with a particular focus on randomised 
controlled trials incorporating the energy value of nuts 
into the total diet. There is also a need for the transparent 
registration of trial protocols, as well as appropriate 
dietary controls. These could include healthy dietary 
patterns (not including nuts), with a greater emphasis on 
dietary modelling required to ensure nutrient intakes are 
matched between control and intervention groups, mini-
mising the risk of confounding.
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